--------- Forwarded message ----------
From: CenterWatch Patient Notification Service <[log in to unmask]>
To: "[log in to unmask]" <[log in to unmask]>
Date: Thu, 27 Sep 2001 20:57:29 -0500
Subject: CenterWatch Email Notification Service
Message-ID: <[log in to unmask]>
Centerwatch homepage is www.centerwatch.com
where you can find information on many more current trials
Announcement of 2 new clinical trials:
1) DCR#:2105-Understanding the effects of apomorphine in late stage
Parkinson's Disease. This study is being conducted in:
- Kansas City, KS
(http://www.centerwatch.com/patient/studies/stu28993.html)
Summary: DCR#:2105-Understanding the effects of apomorphine in late stage
Parkinson's Disease
A clinical trial to gain additional understanding of the beneficial
effects and the side effects of apomorphine in late stage Parkinson's
Disease.
Inclusion:
Age 18 years or older
Male or female (Non-pregnant, non-lactating, taking acceptable form of
contraception)
Diagnosis of Parkinson's Disease
Oral antiparkinson medication (levodopa/carbidopa)
Exclusion:
Prior exposure to apomorphine
Psychoses or dementia (mental deterioration)
Drug or alcohol dependency history one year prior
Significant disease of heart, blood, liver, kidney, metabolism,
respiratory, stomach/intestine, or glands within 3 months prior to study
Allergy to Morphine or Sulfur
Treatment with any investigational drug 30 days prior study
Contact:
Amy Montgomery, Study Coordinator
University of Kansas Medical Center Research Institute
3901 Rainbow Boulevard
Kansas City, KS 66160
Telephone: 913-588-7179
Fax: 913-588-6920
Email: [log in to unmask]
2) DCR#:2181-Parkinson's Disease. This study is being conducted in:
- Kansas City, KS
(http://www.centerwatch.com/patient/studies/stu29010.html)
Trial Information
Summary: DCR#:2181-Parkinson's Disease
A clinical trial to evaluate the safety and effectiveness of different
dosing regimes (change in drug amount over time) of an experimental
slow-release form of ropinirole.
Inclusion:
Men or women aged
30-85 years old inclusively
Women of child-bearing potential must be using an acceptable method of
birth-control (such as oral contraception, surgical sterilization, IUD,
or diaphragm in addition to spermicidal foam and condom on the male
partner, or the norplant system) during the study and for at least one
month prior to and one month following the study
Diagnosis of idiopathic (unknown origin) Parkinson's Disease
Candidate for dopaminergic therapy
Provide written informed consent prior to performing any screening
assessments, including any washout of other medications in preparation
for this study.
Exclusion:
Presence, or history within the previous 3 months, of significant and/or
uncontrolled psychiatric, blood, kidney, liver, glands, neurological,
(other than Parkinson's Disease), or heart disease
Certain abnormal blood levels
Recent history of moderate to severe dizziness, syncope (sudden drop in
blood pressure causing fainting), a fall in blood pressure in an erect
position (like sitting-up or standing)
Significant sleep disorders
An erect blood pressure of greater than 150/90
Participation in a previous clinical trial with the experimental drug
Previous treatment with any L-dopa dose or preparation for more than 6
weeks
History of any dopaminergic treatments within 2 weeks prior to start of
study
Withdrawal, introduction, or change in dose of hormone replacement
therapy
Definite or suspected personal or family history of hypersensitivity to
ropinirole or to drugs similar in chemical structure
Use of any investigational drug within the last 30 days
Recent history of drug dependence or abuse of alcohol
Pregnant or breast-feeding
Contact:
Jovianna Wellinghoff, Study Coordinator
University of Kansas Medical Center Research Institute
3901 Rainbow Boulevard
Kansas City, KS 66160
Telephone: 913-588-5250
Fax: 913-588-6920
Email: [log in to unmask]
----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn
